Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
IRONthis companyDisc Medicine, Inc.	$79.09	-13.21×	3.79×	0×	-13.05×	-97.1%	0.0%	0.0%	0.0%	-28.7%	-30.6%	-6.5%	0×	0.43×	-65.43×	21.94×	0.0%	1	18.78	2	C
AGIOAgios Pharmaceuticals, Inc.	$30.31	-3.82×	1.32×	29.21×	-3.74×	-87.2%	78.7%	-873.9%	-764.0%	-34.6%	-38.2%	-23.9%	0.03×	0.12×	0×	11.46×	0.0%	3	11.59	2	C
COAGHemab Therapeutics Holdings, Inc. Common Stock	$44.84	-14.59×	-5.28×	0×	-12.12×	-92.6%	0.0%	0.0%	0.0%	36.2%	-37.8%	-6.6%	-0.01×	1.24×	0×	18.03×	0.0%	—	—	2	C+
DMRADamora Therapeutics, Inc.	$24.11	-0.15×	0.13×	0×	1.08×	776.2%	0.0%	0.0%	0.0%	-87.3%	-87.7%	-21.4%	0×	1.23×	0×	12.98×	0.0%	3	26.87	1	D+
GERNGeron Corporation	$0.99	-10.15×	3.9×	4.79×	-20.26×	-808.4%	97.4%	-29.3%	-46.7%	-38.0%	-11.3%	-12.6%	1.11×	-3.32×	-1.65×	4.66×	0.0%	1	-2.78	1	C-
PTGXProtagonist Therapeutics, Inc.	$136.77	-42.6×	9.03×	120.66×	-42.45×	-106.5%	97.3%	-343.6%	-282.8%	-21.2%	-25.2%	1.0%	0.02×	0.92×	0×	12.71×	0.0%	6	124.17	3	B-
Peer median	—	-10.15×	1.32×	4.79×	-12.12×	-92.6%	78.7%	-29.3%	-46.7%	-34.6%	-37.8%	-12.6%	0.02×	0.92×	0×	12.71×	0.0%	3	19.23	2	—